Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Eurostars. Búsqueda de empresas e instituciones con experiencia en mecanismos de resistencia antimicrobiana para desarrollar nanocápsulas biodegradables multifuncionales contra enfermedades bacterianas

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDES20190328002
Publicado:
01/04/2019
Caducidad:
31/05/2019
Resumen:
Una pyme española con experiencia en desarrollar y fabricar micro y nanocápsulas de poliuretano biodegradables está preparando una propuesta Eurostars con el fin de desarrollar nanocápsulas biodegradables multifuncionales contra enfermedades bacterianas. La empresa busca investigadores con un profundo conocimiento en medicamentos antimicrobianos y sus mecanismos de resistencia para establecer una cooperación técnica y llevar a cabo la validación preclínica in vitro e in vivo. La nanoencapsulación podría ofrecer soluciones para superar algunas barreras en la eficacia de medicamentos antimicrobianos. Teniendo en cuenta la experiencia previa de la empresa con nanocápsulas de poliuretano/poliurea biodegradables, pueden contribuir a evitar la mayoría de mecanismos de resistencia desarrollados por Pseudomonas Aeruginosa. La fecha límite de la convocatoria es el 12 de septiembre de 2019 y el plazo para presentar expresiones de interés finaliza el 31 de mayo.

Details

Tittle:
Eurostars: Companies and Institutions experienced in antimicrobial and resistance mechanisms sought to develop multifunctional biodegradable nanocapsules against bacterial diseases.
Summary:
Spanish SME experienced in the development and manufacturing of biodegradable polyurethane micro and nanocapsules is preparing a Eurostars proposal. The aim is to develop multifunctional biodegradable nanocapsules against bacterial diseases. Research partners with a deep understanding of antimicrobial drugs and their resistance mechanisms are sought for a research cooperation to perform the in vitro and in vivo pre-clinical validation.
Description:
Current medicine is very focused on the development of new therapies against multi-drug resistant (MDR) bacterial infections. The World Health Organisation (WHO) expects that in 2050 infectious diseases caused by deadly bacteria will be the principal cause of mortality in Europe.
Spanish SME focused on the development of biodegradable polyurethane micro and nanocapsules for industrial, personal care and pharmaceuticals sectors specializes in the synthesis of nanopolymeric entities to selectively deliver chemical or therapeutic entities.
After more than 10 years of collaborative research, the company has introduced a novel technological platform in the field of Drug Delivery Systems (DDS).
This innovative technology could be very conveniently implemented in bacterial infections therapy. It is able to create authentic all-in-one nanosystems with biodegradability, targeting, penetrating and multi drug encapsulation properties.
With this multifunctional DDS, it could be possible to enhance antibacterial drugs pharmacokinetics and efficacy in intravenous, inhalation, oral or topic administration. Similarly, it would be possible to reduce the therapeutic concentration of the drug, thus lowering its side effects.
The SME wants to develop nanoencapsulated systems using well-known antimicrobial-drugs, with difficulties to overcome adaptive resistance in one of the deathliest opportunistic pathogen: Pseudomonas Aeruginosa. Specially, carbapenem-resistant Pseudomonas Aeruginosa has been raised at critical level in WHO´s rank for bacterial infections for which are needed novel antibiotic therapies. Pseudomonas Aeruginosa is a Gram-negative bacterium which commonly causes several nosocomial and life-threatening infections in patients with cystic fibrosis, burn wounds and pulmonary infections. This is a major cause of hospital-acquired infections in patients.
In this context, nanoencapsulation could provide solutions to overcome some barriers in the efficacy of antimicrobial-drugs.
Based on the company´s previous experience with biodegradable polyurethane/polyurea nanocapsules, they can contribute to avoid most of the anti-microbial resistance mechanisms developed by Pseudomonas Aeruginosa. Once encapsulated, the antimicrobial-drug would not be affected by bacterial-released enzymes that would degrade or restrain it. Moreover, external media close to the bacterial cells neither would interact with the drug. This fact allows us to put unstable antimicrobial-drugs in direct contact with the active infection bacteria.
Additionally, for combination therapies treating a broader spectrum of bacterial infections, it is possible to co-encapsulate two or more drugs (hydrophobic-hydrophobic, hydrophilic-hydrophilic or hydrophobic-hydrophilic drugs combination).
Through nanocapsule shell functionalization with biofilm-targeted and/or biofilm-penetrating motifs, nanocapsules could penetrate through biofilms secretions, thus driving drugs onto inaccessible bacterial colonies.
The Spanish company is willing to lead a powerful consortium based on innovative encapsulated antibiotic drugs that can potentially disrupt the way we treat infections. Thus medical and biological partners with a deep understanding of antimicrobial drugs and their resistance mechanisms to perform advanced preclinical assays are sought.
The project will encompass from lab developing of nanoparticles to testing them in preclinical analysis in vitro as well as in vivo. The outcome of the project would be to patent the product, create a spin-off and obtain funding to perform clinical phases 2 years after the project finalization. Partners who want to be part of this collaboration must come from the eligible countries considered in Eurostars´ bases and they have to check the finance method with their National Project Coordinator.
Deadline of the call: 12th September 2019
Deadline for EOI: 31st May 2019
Stage of Development:
Proposal under development
Comments Regarding IPR Status:
Freedom to operate of this technology is covered at European level by owned patents

Partner sought

Partner Sought:
The Spanish company as a consortium leader seeks research agreements with hospitals groups, research entities or biotech and/or pharmaceutical enterprises which are also interested in this medical field. The SME offers all of its know-how and infrastructure on the synthesis of polyurethane nanocapsules and its physical and chemical characterization and evaluation, and the partners should perform the in vitro and in vivo pre-clinical tests. Specifically, the SME is looking for partners with experience in: - In vitro tests to verify the drug selectivity and delivery to the chosen bacteria, the nanocapsules efficiency and the interaction with biofilms. - In vivo assays to test the biodistribution and efficacy.
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Dissemination

Programme-call

Framwork Programme:
Eureka
Coordinator Required:
No
Deadline for Call:
12/09/2019
Weblink to the Call: